News

Public · Published

Canaccord Genuity maintains DexCom at Buy, raises price target to $97 from $90

Canaccord Genuity kept its Buy rating on DexCom and raised its price target to $97 from $90. The new target is 7.8% higher than its previous target and implies 17.9% upside from DexCom's Oct. 30 closing price of $82.29.

Published:

Updated:

What happened

Canaccord Genuity kept its Buy rating on DexCom and raised its price target to $97 from $90. The new target is 7.8% higher than its previous target and implies 17.9% upside from DexCom’s Oct. 30 closing price of $82.29.

Confirmed

Global impact / market context

The higher target signals greater expected share-price appreciation from Canaccord, but it does not change the firm’s Buy rating. If investors act on the more optimistic view, their buying or selling could influence DexCom’s share price; the article reports no change to the company’s operations or finances.

Analyst inference

Analyst views remain spread out: the five recent price targets listed range from $85 to $120, while Canaccord’s new target is $97. This gap shows that analysts differ in their expectations, so one higher target does not represent a shared forecast.

Confirmed

What to watch

  1. Check whether Canaccord publishes further changes to its rating or $97 target; a later revision would show whether its more optimistic estimate is sustained. Analyst inference
  2. Compare future analyst targets with the listed $85–$120 range; targets moving closer together or farther apart would indicate changing agreement about DexCom’s shares. Analyst inference
  3. Watch whether DexCom’s share price moves toward or away from Canaccord’s $97 target; the article gives $82.29 as the Oct. 30 close. Analyst inference

Evidence

  • Original source link unavailable